Tools   Select Another Resource Report Type

http://ki.se/forskning/kol-vaxande-epidemi-i-rokningens-spar

Aims to explore heritability for clinically confirmed chronic obstructive lung disease (COPD), estimate the heritability for lung function and investigate interactions between smoking and genes including the genetic effect on smoking habits. Study participants have been recruited from the Swedish Twin Registry. Types of samples * EDTA whole blood * DNA * Plasma * Serum Number of sample donors: 386 (sample collection completed)

Proper citation: KI Biobank - KOL (RRID:SCR_005782) Copy   

•   Source: SciCrunch Registry

http://www.rmtb.org/

The Rocky Mountain Tissue Bank is a Colorado, 501c3 non-profit corporation, established in 1980. It is governed by a Board of Directors and is an independent tissue processing facility with no affiliation with any other tissue bank. It develops and produces irradiated allogenic cancellous bone and marrow for human transplantation. This product stimulates bone regeneration in patients with bone loss due to trauma, disease, or genetic malformation and provides a foundation for dental implants. The primary distribution network is through Periodontists, and Oral Surgeons and clinicians specializing in implant dentistry.

Proper citation: Rocky Mountain Tissue Bank (RRID:SCR_004847) Copy   

•   Source: SciCrunch Registry

http://ki.se/en/meb/satsa-the-swedish-adoptiontwin-study-of-aging

Longitudinal twin study to understand individual differences in aging with corresponding data and biological samples. The twin design and the inclusion of twins reared apart makes it possible to study the importance of genetic and environmental factors that may underlie differing aging outcomes. Further, the broad spectrum of biological, psychological, and social domains assessed across the life span makes it possible to study patterns of change within and across domains and how these predict health and diseases of aging. The study is comprised of several longitudinal components including, a comprehensive questionnaire that was sent to all twins in the Swedish Twin Registry who were separated at an early age and reared apart and a control sample of twins reared together. The questionnaires include items concerning rearing, family, adult, and working environment, health status, health related behaviors (e.g. alcohol, tobacco, and dietary habits) as well as relationships, and personality measures. The questionnaires were sent again at 3 year intervals in 1987, 1990, 1993 and after a break again in 2004, 2007, and 2010. Thus far more than 2,000 twins have responded to at least one of the seven questionnaire assessments conducted between 1984 and 2010. Additionally there is information about midlife life style factors from the Swedish Twin Registry that were collected about twenty years before SATSA started. In the second component a subsample of 861 individuals have participated in at least one wave of in-person testing (IPT). The first IPT started in 1986 and since then eight IPTs have been collected and the last wave will be collected during 2012-2013. The IPT includes a health examination, structured interviews, tests of functional capacity, and memory and thinking abilities. To date, over 76% of the sample has participated in 3 or more measurement waves. At IPT9 a third component was added to SATSA, a measure of day-to-day fluctuations in memory and thinking abilities, and emotions. Information about social interactions is also collected. After the visit by the research nurses the twins fill out the day-to-day booklet during the next five days. This procedure will be repeated in IPT10. This will add information about small and short-term changes and more changes are supposed to indicate the beginning of poor health. Data from SATSA can be used to study various aspects of aging. For example, the relative importance of genetic and environmental factors for individual differences in aging especially in cognitive and physical domains has been studied. A further main focus is to study changes within and across domains and which genetic and life style factors predict these changes. Given the wide spectrum of data from measured genes to social relationships collected over more than two decades they dare to say that SATSA is a unique study, with the possibility to answer many questions within gerontology and geriatrics. Types of samples * Serum * DNA Number of sample donors: 674 (June 2010)

Proper citation: KI Biobank - SATSA (RRID:SCR_005966) Copy   

•   Source: SciCrunch Registry

http://pathology.wustl.edu/research/tissue.php

The Tissue Procurement Core Facility and Tumor Bank is a collaborative effort between the Siteman Cancer Center and the Department of Pathology and Immunology. This shared resource facility provides the resources, infrastructure, and technologies for biospecimen-based translational pathology research. Services include: Tissue Procurement, Processing, and Storage; Archival Frozen Tissue Bank; and Laser Capture Microdissection. * Tissue Procurement, Processing, and Storage: For investigators initiating new protocols that involve biospecimen collection (e.g. solid tissues, blood, bone marrow), the Core can provide model consent forms and personnel to collect specimens through the Division of Surgical Pathology and other clinical sites on campus. Solid tissues are usually snap frozen in the surgical pathology suite, although investigators may request alternate preservation methods. Blood specimens are generally processed to frozen serum aliquots and peripheral leukocyte cell pellets. Other specimens (e.g. lymph node needle aspirations) that may be obtained in a variety of other patient care areas can be collected and processed immediately by a staff member who is on call at all times to receive specimens. * Archival Frozen Tissue Bank: For investigators desiring immediate access to material for molecular and histological studies, an archive of over 18,000 frozen human biospecimens is available. Specimens include solid tumors, patient-matched non-malignant tissue, serum, and peripheral blood leukocytes. Each specimen is accompanied with basic patient demographic information and pathology diagnostic data. Generally, each frozen tissue specimen is reviewed to confirm that the specimen is representative of the written pathology diagnosis. Investigators may request frozen tissue sections for immunohistochemical analysis, genomic DNA, protein extracts, or cellular RNA derived from any specimen in the archive. * RNA Assessment: Cellular RNA prepared by the Core from banked specimens or any other RNA submitted by investigators can be qualitatively assessed by Agilent Bioanalyzer capillary microelectrophoresis and quantified by fiberoptic spectrophotometry, prior to use for downstream applications such as microarray or qRT-PCR analysis. * Laser Capture Microdissection: Pure cell populations are often needed for clonality, loss of heterozygosity (LOH), gene mutation, and mRNA expression analysis studies. The Core''s Pixcell II Laser Capture Microdissection (LCM) instrument can be used to dissect pure populations of cells from heterogeneous tissue sections. The instrument greatly enhances the speed and ease of dissection as compared to traditional manual methods. The instrument is available for use to investigators who wish to microdissect cells from either specimens stored in the Tissue Procurement Core or their own sets of collected tissue specimens.

Proper citation: Washington University Tissue Bank (RRID:SCR_004876) Copy   

•   Source: SciCrunch Registry

http://www.tmf-ev.de/BiobankenRegisterEN/Registry.aspx

German biobank registry containing names, addresses of the contact persons, web links and basic information of the biobanks. The Registry is available in German and English and is organized by content and by region. The goal is to create public awareness and understanding of the objectives and functions of biobanks, and to arrange collaborations between scientists. The registry cooperates with the European initiative Biobanking and Biomolecular Resources Research Infrastructure (BBMRI). Currently the first phase is implemented as an open access registry. A further expansion is planned with the possibility of online data entry and correction. The German Biobank Registry should help scientists and researchers, but also the interested public as an information gateway to serve. The functions of the registry are: * providing a publicly available registry of the medically relevant biobanks in Germany * improving the national and international visibility of German biobanks; * provision of partners for cooperation; * networking among biobanks; * promoting the exchange of information and of samples between research groups and institutions (hospitals, research institutes and pharmaceutical and biotech companies) operating biobanks; * improved use of existing resources; * promotion of transparency and understanding of the objectives and functions of biobanks in the general public; * Establishing a community to develop common solutions for legal and regulatory issues and thus avoiding redundant expenses for the individual researcher; * provide a planning basis for selective and efficient investments in new biobanks and the expansion of the existing infrastructure. The TMF is cooperating with the European BBMRI project to improve the biobank infrastructure in Europe. Data collection for the national registry is consistent with the survey of BBMRI project. You have to sample the data of your biobank only once and your biobank will be visible nationally and internationally. On the last page of the questionnaire you can give your consent for the use and publication of data for both projects (TMF and BBMRI) specifically. If you participate in the survey that has been harmonized for use throughout Europe by the BBMRI your biobank will be presented to the scientific community, potential partners for cooperations, funding organizations and sponsors. Furthermore, the survey provides an overview of the existing biobank infrastructure in Germany, and by this supports plans to ensure the sustainability and international competitiveness of German biobanks and the necessity of further financial support.

Proper citation: German Biobank Registry (RRID:SCR_004991) Copy   

•   Source: SciCrunch Registry

https://www.davincieuropeanbiobank.org/

BioBank that collects, stores, processes and distributes biospecimens and the associated data. The biospecimens are human and non-human genetic materials, proteins, cells, tissues and biofluids. The data are the biological information associated to the samples and, in the case of human samples, the clinical information pertaining to the donor. The da Vinci European BioBank (daVEB) is a multicenter biobank with a centralized IT infrastructure and a main repository located at the Polo Scientifico (Scientific Campus of the University of Florence) in Sesto Fiorentino (Florence, Italy). Hosted by the Magnetic Resonance Center (CERM), an expert center on protein structure and metabolomics, daVEB's aim is to host as rich as possible biological human sample collections, stored accordingly to EU guidelines, in order to offer a powerful tool in the study of complex diseases. At the end of July 2011, the da Vinci European BioBank of the Pharmacogenomics FiorGen Onlus Foundation has been audited and got the quality certification according to UNI EN ISO 9001:2008 for Collection, storage and distribution of biological samples and the associated data for scientific research. Besides the samples stored at da Vinci European BioBank in Sesto Fiorentino (Florence), the daVEB is also the administrative biobank for research sample collections that are stored in the delocalized repositories. All the sample collections must be registered in the biobank: * sample collections taken within the regular health care * samples taken from healthy individuals or other persons out of the regular health care * samples that have been taken in hospitals within research protocols on specific pathologies all transferred to daVEB endowed with a transfer agreement signed by the donor. The Research Units actually afferent to daVEB are delocalized in the Florence, Prato, Pisa and Siena provinces. Delocalized repositories are under construction in Tuscany.

Proper citation: da Vinci European Biobank (RRID:SCR_004908) Copy   

•   Source: SciCrunch Registry

http://godot.urol.uic.edu/andrology/index.php

The University Andrology Laboratory provides physicians and their patients with all forms of male infertility testing, as well as operating a Patient Sperm Banking Program. This full-service facility is dedicated to the diagnosis and treatment of the infertile male using the highest standard of quality of care. Patients can either visit the main laboratory facility on the University of Illinois at Chicago Medical Center campus or visit our satellite laboratory on North Michigan Avenue. Now available through the University Andrology Laboratory is the OverNiteMale Program. The OverNiteMale Program is particularly convenient for patients who are unable to make a personal visit to one of our laboratories to produce a sample. Patients can now produce a sample in the privacy of their own home from any location in the U.S.A. and send it via Federal Express directly to our laboratory. In-patients can also take advantage of the OverNiteMaleTM Program during their hospital stay. The University Andrology Laboratory was originally introduced at Michael Reese Hospital in Chicago in 1982 and relocated in 1996 to the University of Illinois at Chicago Medical Center, Department of Urology. The laboratory meets the highest standard of quality control and quality assurance. The operation of the University Andrology Laboratory has been under the direction of Gail S. Prins, Ph.D., HCLD, from its inception to the present.

Proper citation: University Andrology Laboratory (RRID:SCR_004901) Copy   

•   Source: SciCrunch Registry

http://www.cancerbiobank.org/

CCPRB (Cancer Control using Population-based Registries and Biobanks) is a Network of Excellence project within the sixth framework programme of the European Union. It is aiming at improved control of cancer by facilitating research linking biobanks and cancer registries. The project involves a systematic quality assurance and continuous development of standards and norms for human sample biobanks in Europe, as well as development of improved integrity-protection standards in the handling of sensitive information in connection with biobank-based research. The samples in the biobanks will be used in large-scale cancer research searching for genetic and infectious causes to cancer, in particular in the areas of breast and colorectal cancer and childhood leukemia. Project objectives: * Provide the study base for uniquely large population-based prospective studies on cancer * Define and implement a generally applicable European Quality Standard for Biobanking that will include improved data and specimen standardization, acquisition and analysis, reliable and standardized statistical analysis as well as improved management and co-ordination of European biobanks. * Define and promote the implementation of integrity-proof methods for biobank-based research involving well defined and secure third party code-keeping systems. * Enable large-scale, population-based research on: ** evaluation of cancer treatment and role of molecular markers in treatment selection ** use over-generation registry linkages applied to large biobank cohorts to identify and evaluate genetic predisposition associated with increased cancer risk as well as interactions with common environmental exposures. ** use over-generation registry linkages applied to large biobank cohorts to explore and evaluate intrauterine exposures associated with increased cancer risk ** exploit the power of large population cohorts for design of optimal strategies for cancer prevention and its evaluation. * Establish a Europe-wide network for spreading the awareness of i) the data, samples and knowledge generated European biobank-based research ii) possibilities for future biobank-based research and iii) the best practice quality standards for biobank-based research.

Proper citation: Cancer Control using Population-based Registries and Biobanks (RRID:SCR_004902) Copy   

•   Source: SciCrunch Registry

http://ccr.coriell.org/Sections/Collections/USIDNET/?SsId=15

The USIDNET DNA and Cell Repository has been established as part of an NIH-funded program - the US Immunodeficiency Network - to provide a resource of DNA and functional lymphoid cells obtained from patients with various primary immunodeficiency diseases. These uncommon disorders include patients with defects in T cell, B cell and/or granulocyte function as well as patients with abnormalities in antibodies / immunoglobulins, complement and other host defense mechanisms. All samples in this Repository have been de-identified to protect the privacy of the individual donors. The USIDNET also operates a Patient Data Registry in addition to this Repository and certain clinical data relating to a specific sample may be available through the Registry for some of the patient samples in the Repository collection. Materials in the collection are being made available at modest cost to qualified investigators in academic and commercial organizations in an effort to stimulate research to increase understanding of these orphan diseases and to promote development of new treatments. Requestors are required to complete a Statement of Research Intent briefly describing their proposed use of materials obtained from the Repository and must sign an Assurance agreeing to conditions established by USIDNET for distribution of samples from its collection. Requestors wishing to obtain additional clinical data specific to individual samples in the Repository collection must make a separate application for that information to the Registry (see www.usidnet.org) Physicians or Patients wishing to submit cell samples for the Repository collection should first contact Coriell to arrange for the Repository to send them the correct sample collection tubes as well as prepaid mailers for returning the collected sample(s) to Coriell. Separate collection and shipping procedures may be involved depending on how many samples are to be shipped at one time and whether the shipment will involve freshly obtained blood or already established cell lines.

Proper citation: USIDNET DNA and Cell Repository (RRID:SCR_004661) Copy   

•   Source: SciCrunch Registry

http://ki.se/ki/jsp/polopoly.jsp?d=29332&a=23686&l=en

THIS RESOURCE IS NO LONGER IN SERVICE, documented August 22, 2016. The original aim of this study was to increase our understanding of the etiology of malignant lymphomas, especially in view of the increasing trend in incidence. Malignant lymphoma (including non-Hodgkin lymphoma, NHL, Hodgkin lymphoma, HL, and chronic lymphocytic leukemia, CLL) constitute a heterogeneous group of malignancies with regard to histology, molecular characteristics and clinical course. Etiological factors may also vary by lymphoma subtype. The incidence of NHL, the most common lymphoma group, has increased dramatically during the past decades in Sweden and in many other Western countries. The reasons for this increase as well as for the majority of all new cases is not well understood. Well established risk factors for lymphoma overall include hereditary and acquired disorders of strong immune dysfunction such as HIV/AIDS and organ transplantation, but they explain few new cases in the population. Approach: Population-based case-control study in Sweden and Denmark. The study includes in total 3740 patients and 3187 controls in both countries recruited during the period October 1999 to October 2002. Through a rapid case ascertainment system, the cases were identified shortly after diagnosis. The controls were randomly selected from national population registers and frequency-matched to the expected number of cases by sex and age group. Both cases and controls were interviewed by telephone based on a standardized questionnaire to obtain detailed information on potential risk factors for lymphoma such as medical history including infectious diseases, drug use and blood transfusions, socio-economic factors and life-style. Blood samples were also collected and stored as serum, plasma, DNA and live lymphocytes. In addition, written questionnaires about dietary habits or work exposures were sent out in Sweden. Tumor material from the cases was re-examined and uniformly classified according to the REAL classification. Status The data collection ended in 2002 and data analysis has been ongoing since then. We have primarily analyzed a range of environmental factors in relation risk of malignant lymphoma subgroups including sun exposure, body mass index, family history of hematopoietic cancer, allergy, autoimmune disorders and mononucleosis. We have also assessed specific genetic determinants in a subgroups of patients with follicular lymphoma and controls. Study results have so far been presented in 14 publications in peer-reviewed journals. In addition to new analyses on other environmental factors, we now also work to understand genetic susceptibility and gene-environmental interaction and risk of lymphoma. Also, prognostic studies have been initiated in collaboration with other research groups with regard to in CLL, HL and T-cell lymphoma.

Proper citation: SCALE - Scandinavian lymphoma etiology (RRID:SCR_006041) Copy   

•   Source: SciCrunch Registry

http://biobanknetwork.telethon.it/

Network of non profit association of Italian repositories to form catalogue of biospecimens and associated data. Used to collect, process, preserve and distribute biological samples and related clinical data from individuals affected by rare diseases, their relatives or from healthy control individuals, with standards complying with Italian laws and international recommendations. You may browse sample catalogue by diagnosis or use advanced search option. Request for samples is granted only if project is in agreement with TNGB mission and after receiving signed material transfer agreement form.

Proper citation: Telethon Network of Genetic Biobanks (RRID:SCR_004658) Copy   

•   Source: SciCrunch Registry

http://www.biobank-suisse.ch/

The foundation biobank-suisse (BBS) is a collaborative network of existing and future research biobanks in Switzerland. The primary goals are: 1. to provide researchers a quick overview of available human biospecimens (by using the web query interface) and up to date person related data; and 2. to provide biobankers with services to further improve the quality of biobanks in Switzerland (e.g. information about up-to-date IT and database software for biobanking; solutions for ethical, legal, and social issues; develop common platform for biobankers; etc.). We maintain a database with data about patients and biospecimens. The database can be queried from our web-site. Once the researcher has found suitable biospecimens we will bring him in contact with the biobanks, which have collected the biospecimen. The researcher and the biobank manager will then discuss the next step without further participation of the foundation biobank-suisse. We provide advice and support to biobank manager, who are in the process to start a biobanking activity for material from humans. Well established biobanks can benefit from our help in realizing specific projects to improve their operations. BBS was founded in December 2005 as an initiative of Oncosuisse and SWISS BRIDGE with the goal to build a collaborative network of existing and future biobanks for research in Switzerland. BBS has currently information from about 60 000 biospecimens and 10 000 patients. This information is provided by the biobanks shown under the Partner biobank menu item and include: * Institut de Pathologie, Centre hospitalier universitaire vaudois (CHUV) * Institut f��r Pathologie Universit��tsspital Basel * Institut f��r Pathologie der Universit��t Bern BBS has entered in a closed collaboration with SAKK''s (Swiss Working Group on Clinical Cancer Research) IT department. BBS''s server is run by SAKK and technical support is provided by the SAKK IT department. BBS is an active member of ISBER (International Society of Biological and Environmental Repositories) the international society of biobanks. BBS also joint BBMRI (an European initiative to build an pan-European network of biobanks.

Proper citation: Biobank Suisse (RRID:SCR_004935) Copy   

•   Source: SciCrunch Registry

http://www.tissuebank.dundee.ac.uk/

Tayside Tissue Bank is a secure bio-repository which holds small samples of surplus tissue and other specimens generously donated by patients who have undergone surgery or other more minor medical procedures during the course of their investigations and treatment. Such samples are vital for medical researchers seeking to improve the detection and treatment of many different diseases as well as advance our understanding of how and why they arise. This website is for both patients who wish to know more about how their tissue is used and for researchers who wish to explore the possibility of utilising the donations kindly made by patients to advance medical research. It also explains some of the additional services the Tissue Bank provides to assist researchers with their investigations including: embedding and cutting sections, standard histological staining, immunohistochemistry (IHC), nucleic acid extraction, protein extraction, and generation of Tissue Microarrays. Donations made to the Bank are held within ultra-low temperature (ULT) freezers within the University of Dundee Medical School at Ninewells Hospital, Dundee. The freezers are alarmed and their temperature continuously monitored. The Bank''s location adjacent to the Pathology Department means it is ideally situated for prompt processing and storage of tissue samples after they have been examined by a pathologist. In addition to collecting, logging and storing tissue samples the bank also holds blood specimens and other materials collected as part of national trials. It also plays a role in administering access to the Tayside Type II diabetes cohort. The Bank contains in the region of 30,000 fresh frozen tissue samples from around 6000 different patients. There are also in excess of 5000 blood samples. Storage of the samples is split between separate, continuously monitored freezers. In addition the Bank has access to the Pathology Department''s Histopathology Archive (30,000 new specimens annually).

Proper citation: Tayside Tissue Bank (RRID:SCR_004927) Copy   

•   Source: SciCrunch Registry

http://www.hemacare.com/

Collects, processes, and distributes human blood products to hospitals and research-related organizations. They operate donor centers and mobile donor vehicles to collect transfusable blood products from healthy donors, and offer human-derived blood products to research organizations. HemaCare also provides blood related services, principally therapeutic apheresis procedures, stem cell collection and other blood treatments, to patients and in connection with clinical trials.

Proper citation: HemaCare Corp. (RRID:SCR_004803) Copy   

•   Source: SciCrunch Registry

https://www.nugene.org/

Collects and stores genetic (DNA) samples along with associated healthcare information from patients of Northwestern-affiliated hospitals and clinics. This resource is available to scientists to conduct groundbreaking genetic research. The information and blood samples provided will be used by researchers to examine the role genes play in the development and treatment of common diseases. The NUgene Project seeks to increase the understanding of genetic mechanisms underlying common diseases, assist in the development of DNA-based technology for diagnosis and treatment of disease, and aid physicians and other healthcare providers in the application of genetics to the practice of medicine. NUgene participants are recruited throughout the Northwestern-affiliated healthcare community in order to create an ethnically and medically diverse population for research. Participants must be 18 years of age or older and receive their medical care from a Northwestern-affiliated provider, regardless of health status. Consenting individuals complete all aspects of enrollment in a single meeting with a research coordinator. The enrollment process includes the donation of a single sample of blood and the completion of a self-administered questionnaire. Participants also sign a consent form during this encounter. The NUgene Project is an interdisciplinary project that relies on the expertise of individuals working in a variety of fields, including science, medicine, clinical research, statistics, epidemiology, and computational biology. NUgene''s multidisciplinary approach has spurred collaborations within Northwestern-affiliated institutions and with other outside institutions. This collaboration of ideas is the future of genetics and genomic research., THIS RESOURCE IS NO LONGER IN SERVICE. Documented on September 16,2025.

Proper citation: NUgene Project (RRID:SCR_007426) Copy   

•   Source: SciCrunch Registry

https://nntc.org/content/relationship-charter

THIS RESOURCE IS NO LONGER IN SERVICE, documented April 14, 2017. Clinical trial designed to determine how central and peripheral nervous system complications of HIV are affected by different histories and regimens of antiretroviral therapy (ART). CHARTER is able to provide fluid specimens, pilot data, and analysis and interpretation expertise for qualified investigators.

Proper citation: CHARTER - CNS HIV Antiretroviral Therapy Effects Research (RRID:SCR_008070) Copy   

•   Source: SciCrunch Registry

http://www.i3crb.fr/

Project to improve data and sample exchanges and to facilitate large scale analysis of data by improving interoperability of French Biological Resources Centres (BRC or biobanks) IT systems and biological databases. The work done in this project will be linked to other national (IBiSA, ANR, R��seau des Biobanques, Club 3C-R), European (BBMRI, ELIXIR) or international project (P3G). In the preliminary phase (2009-2010) I3-CRB has developed a directory of French Biological Resource Centres / Biobanks where one may register their French BRC or perform a search across all of them. Detail by overall data or kingdom is provided as well as many filtering options. Access to biological samples is provided by the participating BRC''''s. Biological Resources Centres (BRC or biobanks) collect annotated biological samples from various sources (human, animal, plant, bacteria...). The type of samples depends on the collection and the associated thematic (DNA, proteins, cells, tissues, blood, serum, organisms...). The aims of these centers are to collect, to store, to transform and to distribute the biological samples. They constitute a vital infrastructure for life science and health research. Goals of the French Biobanks/Biological Resource Centres: * List French biobanks and their biological collections * Improve sample exchanges * Improve the international visibility of the French biological collections MeSH terms have been integrated: Domains, diseases, and location of the disease (Anatomy). Collections/species are based on NCBI Taxonomy.

Proper citation: I3-CRB: Interoperable IT Infrastructure for Biological Resources Centres / Biobanks - France (RRID:SCR_006991) Copy   

•   Source: SciCrunch Registry

http://zfishbook.org/

Collection of revertible protein trap gene-breaking transposon (GBT) insertional mutants in zebrafish with active or cryopreserved lines from initially identified lines. Open to community-wide contributions including expression and functional annotation and represents world-wide central hub for information on how to obtain these lines from diverse members of International Zebrafish Protein Trap Consortium (IZPTC) and integration within other zebrafish community databases including Zebrafish Information Network (ZFIN), Ensembl and National Center for Biotechnology Information. Registration allows users to save their favorite lines for easy access, request lines from Mayo Clinic catalog, contribute to line annotation with appropriate credit, and puts them on optional mailing list for future zfishbook newletters and updates.

Proper citation: zfishbook (RRID:SCR_006896) Copy   

•   Source: SciCrunch Registry

http://www.hdbr.org/

Collection of human embryonic and fetal material (Tissue and RNA) ranging from 3 to 20 weeks of development available to the international scientific community. Material can either be sent to registered users or our In House Gene Expression Service (IHGES) can carry out projects on user''''s behalf, providing high quality images and interpretation of gene expression patterns. Gene expression data emerging from HDBR material is added to our gene expression database which is accessible via our HUDSEN (Human Developmental Studies Network) website. A significant proportion of the material has been cytogenetically karyotyped, and normal karyotyped material is provided for research.

Proper citation: Human Developmental Biology Resource (RRID:SCR_006326) Copy   

•   Source: SciCrunch Registry

http://ki.se/ki/jsp/polopoly.jsp?d=29346&a=31622&l=en

THIS RESOURCE IS NO LONGER IN SERVICE. Documented on May 3rd,2023. Secondary prevention of ischemic heart disease in primary care, a randomized controlled intervention study. The study aims to elucidate if an early, active, group-oriented intervention at the primary care level can decrease the probability of developing a new cardiovascular event within three years, when compared to primary care according to standard protocols. The study also aims at analyzing how the intervention affects parameters as physical activity, eating habits, quality of life, blood pressure, waist measure, and smoking habits. Furthermore, changes in biochemical markers related to glucose- and lipid metabolism, stress related hormone production and sub clinic inflammatory activity as well as the presence of DNA polymorphism in the IL-6- and adiponutrin (ADPN) genes, will be investigated. Types of samples * EDTA whole blood * DNA Number of sample donors: 102 (sample collection completed)

Proper citation: KI Biobank - Sodertaljehjartan (RRID:SCR_006047) Copy   

•   Source: SciCrunch Registry